fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Interest Rates & Oil Jumped As Stocks Headed South This Week – $CORT FSLY $LTRN $NARI $VIX Rise!

By John F. Heerdink, Jr.


Quote of the Day:  “Let us be grateful to people who make us happy, they are the charming gardeners who make our souls blossom.” –  Marcel Proust


Happy Saturday!

I hope that you had a great first week of August and are out enjoying a beautiful weekend day. I am spending my last day in Sonoma and then heading back to San Francisco for the balance of the week. 

As for the broad markets this week, the stock indices headed decidedly south as a number of macroeconomic reports surfaced again including the Fitch Ratings’ downgrade of the US’s credit that disturbed the markets and investors alike and interest rates shot up on the long side of the curve. On Monday, the Chicago PMI report confirmed a rise to 42.8 in July. On Tuesday, the S&P Global US Manufacturing PMI report showed a move up to 49 in the final reading in July. The July ISM Manufacturing Index report also moved higher to 46.4% in July, but remains in contraction territory. The Total construction spending report also showed a rise to .5% M/M in June. The Total private construction report also clocked in with a move up .5% M/M. The total public construction report also confirmed a .3%M/M rise, while on a Y/Y basis total construction spending rose 3.5%. The JOLTS job openings report come in totaling 9.582M in June. On Wednesday, the weekly MBA Mortgage Applications Index report that showed a 3% drop, while purchase & refinance applications both dropped equally buy 3. The ADP Employment Change report came in 324k higher in private sector payrolls in July. The weekly EIA crude oil inventories came in with a 17.1M barrel draw. On Thursday, the Preliminary Q2 Productivity Report came in t 3.7%, while the preliminary Q2 Unit Labor Costs report came in at 1.6%. The Weekly Initial Claims report came in at 227k little higher and the Weekly Continuing Claims report clocked in at 1.7M. The Final July S&P Global US Services PMI report came in lower at 52.3. The June Factory Orders report came in at 2.3% & the July ISM Non-Manufacturing Index report casein at lower 52.7%. On Friday, the Nonfarm payrolls report came in 187k higher in July. The Nonfarm private payrolls report moved up by 172k in July, while the average hourly earnings increased by .4% in July & the unemployment rate dropped to 3.5%. The average workweek also decreased to 34.3 hours. As a result, the yield curve ended the week with  the 2-yr note yield down 7bps to 4.78% & the 10-yr note yield moved up 21bps to 4.06% & the 30-yr yield rose 18 bps to 4.21%. The U.S. Dollar Index also ended up at 1.02.01

The S&P 500 closed at 4,478.03 (-2.3%) for the week and is now up 16.1% YTD as 10 0f the 11 sectors ended in the red with only the energy sector rising 1.2% to end in the green on the strength of oil prices that closed up 2.5% this week at $82.62 & as Russia and Saudi Arabia played their manipulative games again restricting supply. Both Apple (AAPL, $181.99, -7.07% over the last 5-days) & Amazon (AMZN, $139.57, +5.57% over the last 5-days) led the earnings reports headlines throwing their collective weight around as Apple missed expectations and Amazon exceeded. Tesla (TSLA) closed at $253.86, -4.72% over the last 5-days.

The Dow 30 closed above the 35k level again closing at 35,065.60 (-1.1%) this week and is now up 5.8% YTD.  

The Nasdaq closed at 13,909.20 (-.2.8%) and remains up an amazing 32.9% YTD. San Francisco-based Fastly, Inc. (NYSE: FSLY, $9.80,+18.07% over the last 5-days), one of the world’s fastest edge cloud platforms, announced financial results for its second quarter ended June 30, 2023. Fastly highlighted the following: Record second quarter revenue of $122.8 million grew 20% year-over-year and exceeded the high end of our guidance range, Expanded market reach with new packaging and pricing for our core services, making it easy for companies of all sizes to try, buy, and use the powerful Fastly platform, & Repurchased $236.4 million in aggregate principal amount of convertible debt for $195.7 million, reflecting a 17% discount to par, and resulted in a $36.8 million net gain.

The Russell 2000 closed at 1,960.26 (-1.2%) for the week & is now up 11.1% YTD. The MicroCaps also moved higher this week as the iShares Micro-Cap ETF (IWC) closed at $112.82, -1.04% this week & is now up 4.63% YTD.  

Banks stocks pulled back this week after the recent run as The SPDR S&P Regional Banking ETF (KRE) moved down .33% over the last 5-days to close at $46.38 & the SPDR S&P Bank ETF (KBE) also moved down by .12% over the last 5-days to close at $41.89. 

The CBOE Volatility Index (^VIX) closed at $17.10 & up 25.46% over the last 5-days as volatility, fear, & worries increased along with the long term rates. 



As for the biotech sector closed lower again this week,  the Nasdaq Biotechnology ETF (IBB) closed at $127.35, -1.93% over the last 5-days and is now down 3% YTD, the NYSE ARCA Biotech Index (^BTK) closed at 5,178.79, -3% over the last 5-days and is now down 1.94% YTD, & the SPDR S&P Biotech ETF (XBI) closed at $81.22, -3.09% over the last 5-days, & is now down 2.14% YTD. The 52-week range is is now $72.44-$95.18.

On the bright side of the biotech sector this week, Menlo Park, CA’s Corcept Therapeutics Incorporated (NASDAQ: CORT, $31.19, +23.04% over the last 5-days%), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating the effects of the hormone cortisol, today reported results for the quarter ended June 30, 2023. Corcept highlighted the following: Revenue of $117.7 million, a 14 percent increase from second quarter 2022, an Increase in 2023 revenue guidance to $455 – $470 million, from $435 – $455 million, Net income per common share of $0.25 (diluted), compared to $0.24 in second quarter 2022, Cash and investments of $363.3 million as of June 30, 2023 and a Purchase of 6.6 million shares of Corcept common stock for $145.4 million.

Cathie Wood’s ARK Innovation ETF (ARKK) closed at $45.38, -8.21% over the last 5-days and is now up45.26% YTD.   

The iShares U.S. Healthcare ETF (IYH) closed at $278.10, -2.24% over the last 5-days and is now down 1.98% YTD.  

Inari Medical, Inc. (NASDAQ: NARI), $64.38 +10.87% over the last 5-days), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its second quarter ended June 30, 2023. Inari highlighted the following: Generated revenue of $119.0 million in Q2 of 2023, up 28.3% over the same quarter last year, Delivered net income of $2.1 million in Q2 of 2023, compared to a $10.2 million net loss in Q2 of 2022, Announced commitment to PEERLESS II, a randomized controlled trial enrolling up to 1,200 patients, comparing mechanical thrombectomy with FlowTriever versus anti-coagulation alone for the treatment of pulmonary embolism, & Launched two new products, RevCore and T16 Curve, both purpose-built tools designed to address unmet needs in venous thromboembolism (“VTE”) patients.

From the world of cryptocurrency, Bitcoin (BTC) moved to $29,045.49 & down .63% over the course of the last 5-days at the time of the completion of this message. 

Gold prices closed at $1,946, -$25/oz over the last 5-days. Silver prices closed at $23.74, +$.46/oz over the last 5-days. 



VP Watchlist Updates

Lantern Pharma Inc. (NASDAQ: LTRN) closed at $4.84, +5.70% over the last 5-days. Lantern is developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs.Lantern believes that the use of machine learning, genomics and computational methods can help accelerate the development and commercialization of small molecule-based therapies. These drugs can be targeted to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, thereby creating the potential to achieve better outcomes.Their proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. Learn more about Lantern at the VP Watchlist Page.  

Lantern will host its second quarter 2023 operating and financial results webcast on Wednesday, August 9, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial results for the second quarter ended June 30, 2023 and provide guidance on upcoming milestones. Panna Sharma, President and Chief Executive Officer of Lantern Pharma, will lead the call and will be joined by other members of the management team. To register for the webcast, sign up at the link below: https://us06web.zoom.us/webinar/register/1016902973506/WN_h4QZ0ZyxR3mZZbNQxa2eMw.

Lantern also reported that it will participate and present at these upcoming conferences:

  • Society of Neuro-Oncology/American Society of Clinical Oncology CNS Cancer Conference in San Francisco, CA, on August 10th, 2023 from 5:30-7:30 p.m. PT.
    Presentation Title: LP-184, a novel acylfulvene-derived tumor site activated small molecule inhibits adult and pediatric CNS tumor cell growth

  • International Conference on Drug Conjugates for Directed Therapy in Darmstadt, Germany on Thursday, August 24th, 2023 from 9:45-10:15 a.m. CEST.
    Presentation Title: In-silico Approach for the Identification of ADC Targets with Improved Tumor Selectivity

On June 26, Lantern announced the company has published new findings in Oncotarget demonstrating drug candidate LP-284’s in vitro and in vivo antitumor potency for multiple non-Hodgkin’s lymphomas (NHL), including mantle cell lymphoma (MCL) and double-hit lymphoma (DHL). The journal article titled “LP-284 Targets Non-Hodgkin’s Lymphoma and DNA Damage Repair Deficiency” further supports LP-284’s development for NHL and advancement towards a first-in-human Phase 1 trial, which is anticipated for the second half of 2023. Non-Hodgkin’s lymphomas (NHL) remain one of the leading causes of cancer deaths globally and have an estimated 500,000 new cases globally, with NHL being the leading hematological malignancy in the US. Despite advances for NHL using combination and targeted therapies, nearly 20% to 40% of patients with certain subtypes still relapse after treatment. In aggressive subtypes of NHL, like MCL, nearly all patients relapse from standard-of-care (SOC) therapies. READ MORE at this link.

Lantern Pharma collaborates with leading institutions, researchers and companies to develop and deliver cancer therapies. i.e. Johns Hopkins, Fox Chase Cancer Center, Georgetown University, National Cancer Institute, Danish Cancer Society Research Center (DCRC), UT Health San Antonio. Learn more here


 

On Aug. 4, INVO Bioscience, Inc. (Nasdaq: INVO), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture (“IVC”) procedure it enables, today announced the pricing of its public offering of 1,580,000 units, with each unit consisting of one share of common stock and two warrants, each to purchase one share of common stock. Each unit is being sold at a public offering price of $2.85. The warrants will be immediately exercisable at a price of $2.85 per share and will expire five years from the date of issuance. The shares of common stock and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance.

On Aug. 3, INVO announced it has extended the deadline to acquire Wisconsin Fertility Institute (WFI) to August 10, 2023. The acquisition is expected to provide significant scale to the Company’s operations and complement its INVO Center strategy. The Madison-based fertility center primarily offers conventional IVF procedures and generated more than $5 million in revenue and approximately $1.7 million of net income based on fiscal 2022 audited results. “The acquisition of Wisconsin Fertility Institute accelerates the transformation of INVO from a medical device-only company to a healthcare services company, leveraging our unique and innovative INVOcell technology, to help democratize the fertility industry,” commented Steve Shum, CEO of INVO. “Representing our first acquisition, the closing of WFI represents a significantly important addition to our corporate growth plan, which now includes acquiring established and profitable existing practices in addition to building new INVO Centers. Further, the acquisition immediately adds scale and positive cash flow to our operations, with the potential to more than triple our gross revenues. We also expect to drive incremental growth at the clinic with the synergistic introduction of our INVOcell solution. We look forward to finalizing the transaction in the coming days.”

On July 28, INVO effected a 1-for-20 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on July 28, 2023. Commencing with the opening of trading on The Nasdaq Capital Market on July 28, 2023, the Company’s common stock traded on a post-split basis under the same trading symbol, “INVO”. The company now has approximately 842,017 shares of common stock issued and outstanding. In addition, a proportionate adjustment was made to the company’s authorized shares of common stock such that the Company shall have 6,250,000 shares of authorized common stock after the effective time of the reverse stock split.

On June 27, INVO announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to expand the labeling on the INVOcell device and its indication for use to provide for a 5-day incubation period. The data supporting the expanded 5-day incubation clearance demonstrated improved patient outcomes. Steve Shum, CEO of INVO stated, “This is a momentous day for INVO as the FDA has provided clearance for us to expand our labeling to cover a 5-day incubation period for INVOcell. This has been a multi-year effort to demonstrate INVOcell’s ability to improve patient outcomes using a longer incubation period, similar to conventional IVF results. We believe our ability to now communicate the improved success rates using INVOcell to patients and physicians will have a positive effect on the overall confidence and adoption of the technology going forward. The global fertility services market is a substantial, multi-billion-dollar industry and growing, with a significant underserved patient population. INVO’s commercial strategy remains focused on helping to expand affordable care to the underserved patients in need. The Company’s market approach includes the opening of dedicated “INVO Centers” offering INVOcell® and IVC procedure (three centers in North America now operational), the acquisition of existing profitable IVF clinics (signed binding agreements to acquire Wisconsin Fertility Institute), and the continued global distribution and sale of the INVOcell technology solution into existing fertility clinics. We believe the recent 510(k) clearance will help further support our overall commercial activities.”

On April 5, INVO announced that it congratulated the. recently acquired Wisconsin Fertility Institute on being named one of America’s Best Fertility Clinics by Newsweek. During the survey period from November to December 2022, Newsweek and Statista invited over 3,000 reproductive endocrinologists, infertility specialists, obstetricians/gynecologists working in and referring patients to fertility clinics, other medical professionals (e.g., registered nurses, laboratory assistants) and fertility clinic administrators/managers working in fertility clinics to participate in the survey. Participants were asked to assess the quality in five categories for each recommended facility and to assign a ranking position to a set of fertility clinics. Only facilities defined as fertility clinics and ART (“Advanced Reproductive Technology”) providers by the Centers for Disease Control and Prevention (CDC) were considered. Click here for a full listing and methodology for inclusion.

On Jan. 16, BioSpectrum published an article titled “INVO Bioscience introduces next-gen technologies to fertility market in Taiwan.”

Shares of Borqs Technologies, Inc. (Nasdaq: BRQS), a global provider of 5G wireless solutions, Internet of Things (IoT) solutions, and innovative clean energy, with global operations in the U.S., India, and China, closed at $.1722, -13.90% over the last 5-days.

On July 17, Borqs announced its plans to develop an AI-enabled smart watch as part of its expansion strategy into artificial intelligence (AI) for the U.S. market. The AI-enabled smart watch is positioned as an Edge AI device. According to NVIDIA, “Edge AI is the deployment of AI applications in devices throughout the physical world. It’s called “edge AI” because the AI computation is done near the user at the edge of the network, close to where the data is located, rather than centrally in a cloud.” (https://resources.nvidia.com/en-us-it-resources-blogs/what-is-edge-ai) Borqs AI-enabled smart watch will be based on Android and is wirelessly connected via Wifi/BT and cellular networks. It will make use of the AI capability on the watch chipset platform to perform the training and inference of machine learning for the sensors on the watch. The watch will also support ChatGPT or similar AGI capabilities as an intelligent voice assistant. Read more here.

On July 6, Borqs Technologies announced that together with SkyCentrics, they have launched the next generation CTA-2045 ECOPORT communication products. The next-generation products are more price competitive and feature-rich than the current generation products and have significantly better cellular coverage with the use of internal and external antennas. Borqs and SkyCentrics announced their strategic partnership in 2021. The partnership includes joint research & development, sales, and promotion, as well as, Borqs’ investment into SkyCentrics. It will leverage Borqs’ expertise in mobile IoT and 5G technologies. Borqs has years of manufacturing experience in making products worldwide, and has manufactured products for the U.S. mobile operators and Fortune 500 companies. SkyCentrics is an expert in the CTA-2045 and demand response technologies and will be responsible for the CTA-2045 software, ECOPORT certification, and cloud functionality with its Demand Response Energy & Asset Management (DREAM) platform.

The first release of the next generation ECOPORT will start commercial shipment in Q3 in 2023, and both companies forecast strong demand for the products. “I am very pleased that with after one year of development, we’ve successfully developed a suite of very competitive products for the very promising CTA-2045 ECOPORT markets. Together with SkyCentrics, we’ve defined a roadmap for other products which we plan to launch in the latter part of this year as well,” said Pat Chan, CEO of Borqs Technologies.

“With Borqs, we have found a high-quality hardware design and manufacturing partner, which allows us to focus on the software that orchestrates electrical machines in buildings to sync their energy usage to grid prices and carbon emissions. This will enable the grid to support a much larger penetration of intermittent renewable energy, and lower costs for all rate payers,” said Tristan de Frondeville, CEO of SkyCentrics.

A smart city uses various types of electronic methods and sensors to collect data to gain insights in the management and operation of grid loads in order to improve efficiency and effectiveness. As a start in the development of a smart city, mobile connected CTA-2045 devices are chosen by utility companies across the U.S. as the platform for smart management of water heaters, pool pumps and other products with EcoPorts. Historically, all water heaters were ‘dumb,’ controlled by a thermostat and randomly going on and off. The new generation of smart water heaters, connected with CTA-2045 communicating modules can optimize their on/off schedule based on each household’s usage pattern, grid prices and carbon emissions. A key component of electrifying everything is ensuring that all the devices that are electric run on clean energy. It is estimated that the energy savings as well as carbon emission reduction by CTA-2045 controlled residential water heaters can produce staggering results, with each one million CTA-2045 equipped water heaters equating to the removal of 100,000 gasoline powered cars from the highways. Early adoption of CTA-2045 EcoPort enabled water heaters has been underway in low-income multi-family solar and storage communities in Hawaii. Commercial and residential markets in buildings and power grid optimization is estimated to reach $154 billion by the year 2026, according to Verified Market Research in their study “Global Building Automation System Market Size By Technology, By System, By Application, By Geographic Scope And Forecast” (Aug 2020). SkyCentrics is working with major commercial building industrial equipment manufacturers to provide them retrofit kits that will enable their embedded base of existing equipment to be retrofit to have a CTA-2045 EcoPort which will provide an inexpensive way to create the Grid Interactive Efficient Buildings (GEBs) that were recently promoted by the Biden administration quoting the “National Roadmap for Grid Interactive Efficient Buildings” report by The Lawrence Berkeley National Lab and The Brattle Group.



Shares of InMed Pharmaceuticals Inc. (INM), a leader in the research, development and manufacturing of rare cannabinoids, closed at $1.02, down 9.73% over the last 5-days.

  • On July 20, InMed provided a commercial and manufacturing update on its subsidiary BayMedica LLC (“BayMedica”), a leading supplier of bioidentical rare cannabinoids to the Health and Wellness (“H&W”) market. Highlighting the following: $2.3M revenues (unaudited) in Q4 2023, representing 123% increase quarter over quarter (“QoQ”), Optimized and scaled up manufacturing processes over the last 12 months to meet increasing demand, & Third consecutive quarter with significant revenue growth. Eric A. Adams, InMed’s President and CEO stated, “We are very encouraged to see another strong quarter with (unaudited) revenues in excess of $2.3M, representing our third consecutive quarter with significant revenue growth. As demand for minor cannabinoids continues to increase, we see a potential path for BayMedica to become a profitable standalone business subsidiary and contribute margin to the pharmaceutical R&D parent.”

  • On June 22, InMed announced safety and efficacy results from its Phase 2 clinical trial, called 755-201-EB (the “Phase 2 Trial”), for the treatment of symptoms related to EB. The purpose of the Phase 2 Trial was to evaluate the safety of INM-755 CBN cream, which consists of the control cream plus the active pharmaceutical ingredient CBN, and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with EB. All four subtypes of inherited EB, including EB Simplex, Dystrophic EB, Junctional EB, and Kindler Syndrome were accepted into the Phase 2 Trial. The Phase 2 Trial used a within-patient, double-blind design whereby matched index areas were randomized to INM-755 CBN cream or control cream. The Phase 2 Trial enrolled a total of 19 patients. Data from one patient were excluded from efficacy analyses due to a significant protocol deviation. Of the 18 remaining patients whose data were considered reliable for clinical review, 17 were treated for chronic non-wound itch and one patient was treated for wound-related itch. The remaining endpoints (pain, wound healing) could not be analyzed due to too few enrollees with such symptoms. Of the 18 participants assessed, chronic itch improved by a clinically meaningful amount in 12 patients (66.7%). InMed will pursue strategic partnership opportunities for INM-755 in epidermolysis bullosa (“EB”) and other itch-related skin conditions.
  • On June 1, InMed announced that results from a neurodegenerative disease study was presented in a scientific poster at the Canadian Neuroscience Meeting in Montreal from May 28-31, 2023. The InMed sponsored research, entitled “Cannabinoids modulate cytotoxicity and neuritogenesis in Amyloid-beta-treated neuronal cells”, demonstrated the ability of a specific rare cannabinoid (“pCBx”) in InMed’s 900 Series library of potential candidates that reduces amyloid toxicity and tau protein expression while enhancing neuronal cell growth and neuritogenesis markers in vitro, all considered to be important targets in the potential treatment of neurodegenerative diseases such as Alzheimer’s. The research was conducted in the laboratory of Dr. Ujendra Kumar and Dr. Rishi Somvanshi of the faculty of Pharmaceutical Sciences at the University of British Columbia. Studies have shown that cannabinoids, via their endocannabinoid receptors (CB1R and CB2R) that naturally occur in the human body and brain, reduce amyloid-beta (“Aβ”) toxicity, decrease p-tau protein expression and provide neurite outgrowth, thus improving neuronal viability and function. The results presented demonstrate the anti-apoptotic effects of pCBx and its role in neuritogenesis in the cells of neuronal origin and support the role of pCBx as a potential therapeutic intervention in neurodegenerative diseases.
  • On May 31, our sister organization, Tribe Public, hosted a Presentation & Q&A Webinar Event titled “InMed Pharmaceuticals (NASDAQ: INM) Addressing The Increasing Demand For Rare Cannabinoids.” The event was co-hosted by InMed Pharmaceutical’s (NASDAQ: INM) CEO Eric A. Adams, MIBS, & BayMedica’s Jerry P. Griffin, VP, Sales and Marketing. InMed Pharmaceuticals (NASDAQ: INM, $1.34, +6.35%) is a global leader in the development, manufacturing, and commercialization of rare cannabinoids, which is developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. i.e. Alzheimer’s Disease, Glaucoma, & a rare genetic skin disease, Epidermolysis Bullosa (EB). Together with its subsidiary, BayMedica LLC, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. If you missed this event, then you may now watch the event video at the Tribe Public YouTube Channel by clicking here

Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and radiation-induced lung injury, closed at $1.06, -4.50% over the last 5-days and is up 100% YTD.

On July 20 Atossa announced that Health Canada has issued a “No Objection Letter”following the Company’s Clinical Trial Application for its Phase 2 EVANGELINE study. This means Atossa can open sites and enroll patients in their Phase 2 EVANGELINE study throughout Canada.

July 6th, Atossa announced a a strategic, sponsored research agreement with Weill Cornell Medicine to study the potential of inducing estrogen receptor (ER) expression in triple-negative breast cancer (TNBC). The goal of this research is to determine if treating TNBC with extracellular vesicles carrying the ER will convert the tumor to ER+ and render it sensitive to treatment with Selective Estrogen Receptor Modulators (SERM), including Atossa’s proprietary (Z)-endoxifen. The research project will be led by David Lyden, M.D., Ph.D., the Stavros S. Niarchos Professor in Pediatric Cardiology and Director of the Department of Pediatrics’ Physician Scientist Training Program at Weill Cornell Medicine. Dr. Lyden’s laboratory is focused on the molecular pathways activated by tumor extracellular vesicle uptake at the metastatic site and identifying potential therapeutic targets to thwart metastasis. His work has led to a new understanding of how primary tumor cells dictate their own metastases, by decoding how cancer-derived extracellular vesicles mediate intercellular communication. Most recently, Dr. Lyden has identified specific extracellular vesicle subpopulations and discovered a new subset of particles known as exomeres, which collectively have distinct functional roles in the systemic effects of cancer.

On June 28, Atossa and Quantum Leap Healthcare Collaborative™ announced that six patients have been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the ongoing Phase 2 I-SPY 2 clinical trial. (Z)-endoxifen is being evaluated as a neoadjuvant treatment for patients with newly diagnosed estrogen receptor-positive (ER+) invasive breast cancer whose tumors are predicted to be sensitive to endocrine therapy but for whom chemotherapy is expected to provide little or no benefit.

On June 27, Atossa announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $10 million of its common stock through December 31, 2023.

On June 21, Atossa announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11,680,036) directed to enterically encapsulated endoxifen compositions formulated as a suspension. These include all liquid suspension formulations suitable for oral administration and dispersible tablets, powders, granules, pellets or sprinkles for reconstitution, which are commonly used for pediatric administration. A suspension is a heterogeneous mixture. It differs from a solution, which is a homogeneous mixture, in that the particles in a solution are much smaller and are dissolved in a solvent, therefore staying mixed together. In a suspension, the particles are large, do not dissolve, and will separate. Advantages of suspension formulations may include ease of delivery of low soluble therapeutic agents, increased bioavailability of drug dosage, controlled drug delivery and resistance to degradation. Dr. Steven Quay, Atossa’s President and Chief Executive Officer, “Our new patent covering suspension formulations is important as we continue to learn more about the potential therapeutic role of endoxifen beyond breast cancer and mammographic breast density. Suspension formulations are particularly useful in pediatric applications where drugs are often dosed by weight and delivered via powders or sprinkles mixed with food and dispersible tablets, which are easier for children to ingest compared to tablets.”

On June 12, Atossa announced that the pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully enrolled. EVANGELINE is a randomized non-inferiority trial of Atossa’s patented Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, and exemestane plus goserelin as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. The PK run-in cohort consists of six patients, all of whom will be treated with (Z)-endoxifen at 40mg/day for four weeks. The goal of the PK run-in cohort is to determine if the 40mg dose delivers steady-state plasma concentrations (Css) between 500 – 1000 ng/mL, which are optimal to target PKCβ1 inhibition and enhance (Z)-endoxifen’s antitumor mechanism of action. Once the optimal dose of (Z)-endoxifen is determined, the Treatment Cohort will commence. Participants in the treatment cohort will receive neoadjuvant treatment for up to six months, followed by surgery. The study is expected to enroll approximately 175 patients at up to 25 sites across the United States.

 

Azitra, Inc. a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, successfully priced their Initial Public Offering (IPO) on the NYSE with the ticker ‘AZTR’ on Friday, June 16, 2023.  You can learn more about their company today at their website https://azitrainc.com.  On July 19, Azitra announced the addition of two members to its board of directors, biotech leaders Barbara Ryan and John Schroer.


Shares of ADT Inc. (ADT), the most trusted brand in smart home and small business security, closed at $6.34, -.31% over the last 5-days. On May 2, ADT reported results for the first quarter of 2023 highlighting strong year-over-year growth in revenue; CSB and Commercial up 7% and 15%, respectively, versus prior year period, maintained record high customer retention and new record high recurring monthly revenue balance, improved capital efficiency with record revenue payback, & continued deleveraging with over $400 million debt reduction expected in 2023.


Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates and let’s find ways to crush it again as we move forward!

Investing & Inspiration

  1. “Let us be grateful to people who make us happy, they are the charming gardeners who make our souls blossom.” –  Marcel Proust
  2. “Strength and growth come only through continuous effort and struggle.” – Napoleon Hill
  3. “Science may never come up with a better office communication system than the coffee break.” – Earl Wilson
  4. “If everyone is moving forward together, then success takes care of itself.” – Henry Ford
  5. “Hope is like the sun, which, as we journey toward it, casts the shadow of our burden behind us.”– Samuel Smiles
  6. “Patriotism is supporting your country all the time, and your government when it deserves it.” – Mark Twain
  7. “What would life be if we had no courage to attempt anything?” – Vincent Van Gogh
  8. “The biggest risk is not taking any risk… In a world that is changing really quickly, the only strategy that is guaranteed to fail is not taking risks.” – Mark Zuckerberg
  9. “Our lives improve only when we take chances – and the first and most difficult risk we can take is to be honest with ourselves.” – Walter Anderson
  10. “Action is the foundational key to all success.” – Pablo Picasso
  11. “Success is never final, failure is never fatal. It’s courage that counts.” – John Wooden
  12. “Innovation distinguishes between a leader and a follower.” – Steve Jobs
  13. “All the art of living lies in a fine mingling of letting go and holding on.” – Havelock Ellis
  14. “The size of your success is measured by the strength of your desire; the size of your dream; and how you handle disappointment along the way.” – Robert Kiyosaki
  15. “O, wind, if winter comes, can spring be far behind?” – Percy Bysshe Shelley
  16. “Patience is a virtue, and I’m learning patience. It’s a tough lesson.” – Elon Musk
  17. “Be true to your work, your word, and your friend.” – John Boyle O’Reilly
  18. “Believe in yourself! Have faith in your abilities! Without a humble but reasonable confidence in your own powers you cannot be successful or happy.” – Norman Vincent Peale
  19. “Surprise is the greatest gift which life can grant us.” – Boris Pasternak
  20. “Logic will get you from A to B. Imagination will take you everywhere.” – Albert Einstein
  21. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  22. “Do exactly what you would do if you felt most secure.” – Meister Eckhart
  23. “Life lived for tomorrow will always be just a day away from being realized.” – Leo Buscaglia
  24. “Wisdom is oftentimes nearer when we stoop than when we soar.” – Wordsworth
  25. “Take chances, make mistakes. That’s how you grow. Pain nourishes your courage. You have to fail in order to practice being brave.” – Mary Tyler Moore
  26. “A single twig breaks, but the bundle of twigs is strong.” – Tecumseh
  27. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  28. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  29. “The limits of the possible can only be defined by going beyond them into the impossible.” – Arthur C. Clarke
  30. “Be faithful in small things because it is in them that your strength lies.” – Mother Teresa
  31. “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
  32. “By three methods we may learn wisdom: First, by reflection, which is noblest; Second, by imitation, which is easiest; and third by experience, which is the bitterest.” – Confucius
  33. “No man was ever wise by chance.” – Lucius Annaeus Seneca
  34. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  35. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare
  36. “It does not matter how slowly you go as long as you do not stop.” – Confucius

  37. “I want to put a ding in the universe.” – Steve Jobs

  38. “Research is creating new knowledge.” – Neil Armstrong

  39. “The reward for work well done is the opportunity to do more.” – Jonas Salk
  40. “Man is a creative retrospection of nature upon itself.” – Karl Wilhelm Friedrich Schlegel
  41. “There’s something about taking a plow and breaking new ground. It gives you energy.” – Ken Kesey
  42. “Success seems to be largely a matter of hanging on after others have let go.” – William Feather

  43. “The essential conditions of everything you do must be choice, love, passion.” – Nadia Boulanger
  44. “More business is lost every year through neglect than through any other cause.” – Rose Kennedy

  45. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes

  46. “A person who won’t read has no advantage over one who can’t read.” – Mark Twain
  47. “The best way out is always through.” – Robert Frost

  48. “Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.” – Francis of Assisi
  49. “Without labor nothing prospers.” – Sophocles

  50. “Intellectuals solve problems, geniuses prevent them.” – Albert Einstein
  51. “This is the precept by which I have lived: Prepare for the worst; expect the best; and take what comes.” – Hannah Arendt

  52. “The best and most beautiful things in the world cannot be seen or even touched – they must be felt with the heart.” – Helen Keller

  53. “He who is brave is free.” – Lucius Annaeus Seneca
  54. “When something is important enough, you do it even if the odds are not in your favor.” – Elon Musk

  55. “I choose a block of marble and chop off whatever I don’t need.” – Auguste Rodin

  56. “Hope is the only bee that makes honey without flowers.” – Robert Green Ingersoll

  57. “He who knows that enough is enough will always have enough.” – Lao Tzu

  58. “Plans to protect air and water, wilderness and wildlife are in fact plans to protect man.” – Stewart Udall
  59. “In order to carry a positive action we must develop here a positive vision.” – Dalai Lama

  60. “A hero is someone who understands the responsibility that comes with his freedom.” – Bob Dylan
  61. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  62. “If we give something positive to others, it will return to us. If we give negative, that negativity will be returned.” – Allu Arjun
  63. “A good plan violently executed now is better than a perfect plan executed next week.” ~ George S. Patton
  64. “You must do the things you think you cannot do.”- Eleanor Roosevelt
  65. “Success is dependent on effort.” – Sophocles
  66. “Nobody who ever gave his best regretted it.” – George Halas
  67. “Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
  68. “And when I breathed, my breath was lightning.” – Black Elk
  69. “Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
  70. “You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
  71. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  72. “We are an impossibility in an impossible universe.” – Ray Bradbury
  73. “If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
  74. “I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
  75. Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
  76. “It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
  77. “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
  78. Surprise is the greatest gift which life can grant us.” –  Boris Pasternak
  79. “Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran 
  80. “Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
  81. “All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
  82. “There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” –  Colin Powell
  83. “There is more to life than increasing its speed.” – Mahatma Gandhi
  84. “Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
  85. “Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
  86. “Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
  87. “In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
  88. “Life is too short for long-term grudges.” – Elon Musk
  89. There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
  90. “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
  91. “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
  92. “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
  93. “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
  94. “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
  95. “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
  96. “Let there be work, bread, water and salt for all.” – Nelson Mandela
  97. “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
  98. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  99. “I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
  100. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  101. “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
  102. “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
  103. “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
  104. “Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
  105. “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
  106. “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
  107. “Delete the negative; accentuate the positive!” – Donna Karan
  108. “It’s crazy how fast time flies and how things progress.” – Nathan Chen
  109. “The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
  110. “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
  111. “Everything has beauty, but not everyone sees it.” – Confucius
  112. A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
  113. “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
  114. “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
  115. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  116. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  117. “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
  118. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  119. “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
  120. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  121. “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
  122. “No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
  123. “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
  124. “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
  125. “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
  126. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  127. “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
  128. “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
  129. “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
  130. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  131. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  132. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  133. “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
  134. “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
  135. “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese 
  136. “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
  137. “Never do anything against conscience even if the state demands it.”– Albert Einstein
  138. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  139. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  140. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  141. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  142. “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
  143. “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
  144. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
  145. “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
  146. “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch 
  147. “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
  148. “The secret of getting ahead is getting started.” – Mark Twain
  149. “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe

Videos



Post View Count : 501